The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Microbials for the production of monoclonal antibodies and antibody fragments
Open accessAbstract
•Glycosylated full length antibodies are currently produced in mammalian cells.•Antibody fragments can be produced in microbial organisms.•Strain engineering allows production of full length antibodies in microbials.•Microbials provide several advantages over mammalian cells. Monoclonal antibodies (mAbs) and antibody fragments represent the most important biopharmaceutical products today. Because full length antibodies are glycosylated, mammalian cells, which allow human-like N-glycosylation, are currently used for their production. However, mammalian cells have several drawbacks when it comes to bioprocessing and scale-up, resulting in long processing times and elevated costs. By contrast, antibody fragments, that are not glycosylated but still exhibit antigen binding properties, can be produced in microbial organisms, which are easy to manipulate and cultivate. In this review, we summarize recent advances in the expression systems, strain engineering, and production processes for the three main microbials used in antibody and antibody fragment production, namely Saccharomyces cerevisiae, Pichia pastoris, and Escherichia coli. Monoclonal antibodies (mAbs) and antibody fragments represent the most important biopharmaceutical products today. Because full length antibodies are glycosylated, mammalian cells, which allow human-like N-glycosylation, are currently used for their production. However, mammalian cells have several drawbacks when it comes to bioprocessing and scale-up, resulting in long processing times and elevated costs. By contrast, antibody fragments, that are not glycosylated but still exhibit antigen binding properties, can be produced in microbial organisms, which are easy to manipulate and cultivate. In this review, we summarize recent advances in the expression systems, strain engineering, and production processes for the three main microbials used in antibody and antibody fragment production, namely Saccharomyces cerevisiae, Pichia pastoris, and Escherichia coli. IntroductionOver the past three decades, the biopharmaceutical market has become a significant component of the global pharmaceutical market accounting for around 40% of its sales. The use of organisms as biopharmaceutical production factories offers several advantages over chemical synthesis. Microorganisms can produce high molecular weight compounds such as proteins [1Lee J.Y. Bang D. Challenges in the chemical synthesis of average sized proteins: sequential vs. convergent ligation of multiple peptide fragments.Biopolymers. 2010; 94: 441-447Crossref PubMed Scopus (21) Google Scholar] and carry out highly enantio- and regio-selective reactions by their native enzymatic machinery – these reactions are hard to achieve by chemical synthesis. The use of microorganisms also enables repeated implementation of immobilized enzymes or cells resulting in the reduction of the overall production costs [2Bolivar J.M. et al.Shine a light on immobilized enzymes: real-time sensing in solid supported biocatalysts.Trends Biotechnol. 2013; 31: 194-203Abstract Full Text Full Text PDF PubMed Scopus (45) Google Scholar]. Finally, processes employing microorganisms do not generate organic and inorganic pollutants, such as mercury and toluene [3Chelliapan S. Sallis P.J. Removal of organic compound from pharmaceutical wastewater using advanced oxidation processes.J. Sci. Ind. Res. 2013; 72: 248-254Google Scholar].The biopharmaceutical market originated in the late 1970s with the establishment of recombinant DNA techniques. The industrial interest materialized almost immediately and in 1982 the US Food and Drug Administration (FDA) approved the commercialization of humulin, the human insulin analog, recombinantly produced in the bacterium E. coli [4Walsh G. New biopharmaceuticals: a review of new biologic drug approvals over the years, featuring highlights from 2010 and 2011.Process Development Forum. BioPharm International, 2012http://www.processdevelopmentforum.com/articles/new-biopharmaceuticals-a-review-of-new-biologic-drug-approvals-over-the-years-featuring-highlights-from-2010-and-2011/Google Scholar]. For a while the FDA only allowed the transformation of bacteria and the expression of small, non-glycosylated proteins, like insulin, due to concern about introducing new toxicities such as contaminating bacterial substances, which raise immunogenic reactions in patients. However, with the development of selectable resistance markers, like antibiotic resistance markers, and the possibility of production in eukaryotic organisms, the FDA began showing increasing flexibility towards biotechnological innovation, leading to a continually increasing number of approved new biological entities (NBEs). In 2012, the biopharmaceutical market turnover was estimated at around 100–120 billion US dollars per year [5Butler M. Meneses-Acosta A. Recent advances in technology supporting biopharmaceutical production from mammalian cells.Appl. Microbiol. Biotechnol. 2012;
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biopharmaceutical benchmarks 2014
Walsh, G. (2014) · Nature Biotechnology · doi:10.1038/nbt.3040 · Cited by 1,008
Recent Advances in the Expression of Foreign Genes in Pichia pastoris
Cregg, J. M., Vedvick, T. S., & Raschke, W. C. (1993) · Nature Biotechnology · doi:10.1038/nbt0893-905 · Cited by 911
scFv Antibody: Principles and Clinical Application
Ahmad, Z. A., Yeap, S. K., Ali, A. M., Ho, W. Y., Alitheen, N. B. M., & Hamid, M. (2012) · Clinical and Developmental Immunology · doi:10.1155/2012/980250 · Cited by 760
Biopharmaceutical benchmarks 2010
Walsh, G. (2010) · Nature Biotechnology · doi:10.1038/nbt0910-917 · Cited by 756
Cell culture processes for monoclonal antibody production
Li, F., Vijayasankaran, N., Shen, A. (., Kiss, R., & Amanullah, A. (2010) · mAbs · doi:10.4161/mabs.2.5.12720 · Cited by 739
van der Valk, J., Brunner, D., De Smet, K., Fex Svenningsen, Å., Honegger, P., Knudsen, L. E., Lindl, T., Noraberg, J., Price, A., Scarino, M. L., et al. (2010) · Toxicology in Vitro · doi:10.1016/j.tiv.2010.03.016 · Cited by 648
Genome sequence of the recombinant protein production host Pichia pastoris
De Schutter, K., Lin, Y.-C., Tiels, P., Van Hecke, A., Glinka, S., Weber-Lehmann, J., Rouzé, P., Van de Peer, Y., & Callewaert, N. (2009) · Nature Biotechnology · doi:10.1038/nbt.1544 · Cited by 537
Humanization of yeast to produce complex terminally sialylated glycoproteins
Hamilton, S. R., Davidson, R. C., Sethuraman, N., Nett, J. H., Jiang, Y., Rios, S., Bobrowicz, P., Stadheim, T. A., Li, H., Choi, B.-K., et al. (2006) · Science · doi:10.1126/science.1130256 · Cited by 511
Antibody fragments: Hope and hype
Nelson, A. L. (2010) · mAbs · doi:10.4161/mabs.2.1.10786 · Cited by 463
Industrial production of recombinant therapeutics in Escherichia coli and its recent advancements
Huang, C.-J., Lin, H., & Yang, X. (2012) · Journal of Industrial Microbiology and Biotechnology · doi:10.1007/s10295-011-1082-9 · Cited by 424
Production of Complex Human Glycoproteins in Yeast
Hamilton, S. R., Bobrowicz, P., Bobrowicz, B., Davidson, R. C., Li, H., Mitchell, T., Nett, J. H., Rausch, S., Stadheim, T. A., Wischnewski, H., et al. (2003) · Science · doi:10.1126/science.1088166 · Cited by 407
The humanization of N-glycosylation pathways in yeast
Wildt, S., & Gerngross, T. U. (2005) · Nature Reviews Microbiology · doi:10.1038/nrmicro1087 · Cited by 393
Choi, B.-K., Bobrowicz, P., Davidson, R. C., Hamilton, S. R., Kung, D. H., Li, H., Miele, R. G., Nett, J. H., Wildt, S., & Gerngross, T. U. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0931263100 · Cited by 360
Partow, S., Siewers, V., Bjørn, S., Nielsen, J., & Maury, J. (2010) · Yeast · doi:10.1002/yea.1806 · Cited by 334
Advances in Mammalian cell line development technologies for recombinant protein production
Lai, T., Yang, Y., & Ng, S. (2013) · Pharmaceuticals · doi:10.3390/ph6050579 · Cited by 322
Glycosylation engineering in yeast: the advent of fully humanized yeast
Hamilton, S. R., & Gerngross, T. U. (2007) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2007.09.001 · Cited by 322
Näätsaari, L., Mistlberger, B., Ruth, C., Hajek, T., Hartner, F. S., & Glieder, A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039720 · Cited by 281
Self-citationEngineering complex-type N-glycosylation in Pichia pastoris using GlycoSwitch technology
Jacobs, P. P., Geysens, S., Vervecken, W., Contreras, R., & Callewaert, N. (2009) · Nature Protocols · doi:10.1038/nprot.2008.213 · Cited by 270
Berlec, A., & Štrukelj, B. (2013) · Journal of Industrial Microbiology and Biotechnology · doi:10.1007/s10295-013-1235-0 · Cited by 211
Recent advances in technology supporting biopharmaceutical production from mammalian cells
Butler, M., & Meneses-Acosta, A. (2012) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-012-4451-z · Cited by 210
Krainer, F. W., Dietzsch, C., Hajek, T., Herwig, C., Spadiut, O., & Glieder, A. (2012) · Microbial Cell Factories · doi:10.1186/1475-2859-11-22 · Cited by 210
Self-citationEnhancement of protein secretion in Pichia pastoris by overexpression of protein disulfide isomerase
Inan, M., Aryasomayajula, D., Sinha, J., & Meagher, M. M. (2006) · Biotechnology and Bioengineering · doi:10.1002/bit.20762 · Cited by 181
Lin-Cereghino, G. P., Stark, C. M., Kim, D., Chang, J., Shaheen, N., Poerwanto, H., Agari, K., Moua, P., Low, L. K., Tran, N., et al. (2013) · Gene · doi:10.1016/j.gene.2013.01.062 · Cited by 168
Biotechnological applications of recombinant single-domain antibody fragments
de Marco, A. (2011) · Microbial Cell Factories · doi:10.1186/1475-2859-10-44 · Cited by 166
The production of antibody fragments and antibody fusion proteins by yeasts and filamentous fungi
Joosten, V., Lokman, C., van den Hondel, C. A. M. J. J., & Punt, P. J. (2003) · Microbial Cell Factories · doi:10.1186/1475-2859-2-1 · Cited by 159
Modeling of growth and energy metabolism of Pichia pastoris producing a fusion protein
Jahic, M., Rotticci‐Mulder, J. C., Martinelle, M., Hult, K., & Enfors, S. (2002) · Bioprocess and Biosystems Engineering · doi:10.1007/s00449-001-0274-5 · Cited by 152
Chiba, Y., Suzuki, M., Yoshida, S., Yoshida, A., Ikenaga, H., Takeuchi, M., Jigami, Y., & Ichishima, E. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.41.26298 · Cited by 140
New and Redesigned pRS Plasmid Shuttle Vectors for Genetic Manipulation of Saccharomyces cerevisiae
Chee, M. K., & Haase, S. B. (2012) · G3 Genes Genomes Genetics · doi:10.1534/g3.111.001917 · Cited by 136
Production of Secretory and Extracellular N-Linked Glycoproteins inEscherichia coli
Fisher, A. C., Haitjema, C. H., Guarino, C., Çelik, E., Endicott, C. E., Reading, C. A., Merritt, J. H., Ptak, A. C., Zhang, S., & DeLisa, M. P. (2010) · Applied and Environmental Microbiology · doi:10.1128/aem.01901-10 · Cited by 134
Sohn, S. B., Graf, A. B., Kim, T. Y., Gasser, B., Maurer, M., Ferrer, P., Mattanovich, D., & Lee, S. Y. (2010) · Biotechnology Journal · doi:10.1002/biot.201000078 · Cited by 133
Hou, J., Tyo, K. E. J., Liu, Z., Petranović, D., & Nielsen, J. (2012) · Metabolic Engineering · doi:10.1016/j.ymben.2012.01.002 · Cited by 127
Mille, C., Bobrowicz, P., Trinel, P. A., Li, H., Maes, E., Guérardel, Y., Fradin, C., Martinez‐Esparza, M., Davidson, R. C., Janbon, G., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m708825200 · Cited by 105
Soft sensor assisted dynamic bioprocess control: Efficient tools for bioprocess development
Sagmeister, P., Wechselberger, P., Jazini, M., Meitz, A., Langemann, T., & Herwig, C. (2013) · Chemical Engineering Science · doi:10.1016/j.ces.2013.02.069 · Cited by 102
Self-citationProtein transport across and into cell membranes in bacteria and archaea
Yuan, J., Zweers, J. C., van Dijl, J. M., & Dalbey, R. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-009-0160-x · Cited by 102
Improvement of N-glycan site occupancy of therapeutic glycoproteins produced in Pichia pastoris
Choi, B., Warburton, S., Lin, H., Patel, R., Boldogh, I. R., Meehl, M., d′Anjou, M., Pon, L. A., Stadheim, T. A., & Sethuraman, N. (2012) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-012-4067-3 · Cited by 100
Xu, P., Raden, D. L., Doyle, F. J., & Robinson, A. S. (2005) · Metabolic Engineering · doi:10.1016/j.ymben.2005.04.002 · Cited by 85
Lara, A. R., Caspeta, L., Gosset, G., Bolívar, F., & Ramírez, O. T. (2007) · Biotechnology and Bioengineering · doi:10.1002/bit.21664 · Cited by 74
A fast approach to determine a fed batch feeding profile for recombinant Pichia pastoris strains
Dietzsch, C., Oliver Spadiut, A., & Herwig, C. (2011) · Microbial Cell Factories · doi:10.1186/1475-2859-10-85 · Cited by 73
Self-citationCallewaert, N., Laroy, W., Cadirgi, H., Geysens, S., Saelens, X., Jou, W. M., & Contreras, R. (2001) · FEBS Letters · doi:10.1016/s0014-5793(01)02676-x · Cited by 70
N-Linked Glycosylation of Antibody Fragments in Escherichia coli
Lizak, C., Fan, Y., Weber, T. C., & Aebi, M. (2011) · Bioconjugate Chemistry · doi:10.1021/bc100511k · Cited by 69
Plasmid‐free T7‐based Escherichia coli expression systems
Striedner, G., Pfaffenzeller, I., Luchner, M., Nemecek, S., Grabherr, R. M., & Bayer, K. (2009) · Biotechnology and Bioengineering · doi:10.1002/bit.22598 · Cited by 68
Baumann, K., Adelantado, N., Lang, C., Mattanovich, D., & Ferrer, P. (2011) · Microbial Cell Factories · doi:10.1186/1475-2859-10-93 · Cited by 65
Open access to sequence: Browsing the Pichia pastoris genome
Mattanovich, D., Callewaert, N., Rouzé, P., Lin, Y., Graf, A. B., Redl, A., Tiels, P., Gasser, B., & Schutter, K. D. (2009) · Microbial Cell Factories · doi:10.1186/1475-2859-8-53 · Cited by 63
Engineering Fully Human Monoclonal Antibodies from Murine Variable Regions
Bernett, M. J., Karki, S., Moore, G. L., Leung, I., Chen, H., Pong, E., Nguyen, D.-H. T., Jacinto, J. M., Zalevsky, J., Muchhal, U. S., et al. (2010) · Journal of Molecular Biology · doi:10.1016/j.jmb.2009.12.046 · Cited by 63
Mairhofer, J., Cserjan‐Puschmann, M., Striedner, G., Nöbauer, K., Razzazi‐Fazeli, E., & Grabherr, R. M. (2010) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2010.01.025 · Cited by 61
Heat shock response improves heterologous protein secretion in Saccharomyces cerevisiae
Hou, J., Österlund, T., Liu, Z., Petranović, D., & Nielsen, J. (2012) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-012-4596-9 · Cited by 60
Kameyama, Y., Kawabe, Y., Itô, A., & Kamihira, M. (2009) · Biotechnology and Bioengineering · doi:10.1002/bit.22619 · Cited by 59
Davidson, R. C. (2004) · Glycobiology · doi:10.1093/glycob/cwh023 · Cited by 58
Zalai, D., Dietzsch, C., Herwig, C., & Oliver Spadiut, A. (2012) · Biotechnology Progress · doi:10.1002/btpr.1551 · Cited by 50
Self-citationRepressible promoters – A novel tool to generate conditional mutants in Pichia pastoris
Delic, M., Mattanovich, D., & Gasser, B. (2013) · Microbial Cell Factories · doi:10.1186/1475-2859-12-6 · Cited by 48
Sonoda, H., Kumada, Y., Katsuda, T., & Yamaji, H. (2011) · Journal of Bioscience and Bioengineering · doi:10.1016/j.jbiosc.2010.12.015 · Cited by 45
Reconstruction of a bacterial isoprenoid biosynthetic pathway in Saccharomyces cerevisiae
Maury, J., Asadollahi, M. A., Møller, K., Schalk, M., Clark, A., Formenti, L. R., & Nielsen, J. (2008) · FEBS Letters · doi:10.1016/j.febslet.2008.10.045 · Cited by 43
Nett, J. H., Stadheim, T. A., Li, H., Bobrowicz, P., Hamilton, S. R., Davidson, R. C., Choi, B., Mitchell, T., Bobrowicz, B., Rittenhour, A. M., et al. (2010) · Yeast · doi:10.1002/yea.1835 · Cited by 42
Pfeffer, M., Maurer, M., Stadlmann, J., Grass, J., Delic, M., Altmann, F., & Mattanovich, D. (2012) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-012-3933-3 · Cited by 40
Kim, J. Y., Kim, Y., Han, Y. K., Choi, H., Kim, Y. H., & Lee, G. M. (2011) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-011-3106-9 · Cited by 39
Becker, E., Florin, L., Pfizenmaier, K., & Kaufmann, H. (2009) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2009.11.018 · Cited by 38
Elimination of -mannose glycan structures in Pichia pastoris
Hopkins, D., Gomathinayagam, S., Rittenhour, A. M., Du, ., Hoyt, E., Karaveg, K., Mitchell, T., Nett, J. H., Sharkey, N., Stadheim, T. A., et al. (2011) · Glycobiology · doi:10.1093/glycob/cwr108 · Cited by 34
Levy, R., Ahluwalia, K., Bohmann, D. J., Giang, H. M., Schwimmer, L. J., Issafras, H., Reddy, N. B., Chan, C., Horwitz, A. H., & Takeuchi, T. (2013) · Journal of Immunological Methods · doi:10.1016/j.jim.2013.04.010 · Cited by 34
Ferndahl, C., Bonander, N., Logez, C., Wagner, R., Gustafsson, L., Larsson, C., Hedfalk, K., Darby, R. A. J., & Bill, R. M. (2010) · Microbial Cell Factories · doi:10.1186/1475-2859-9-47 · Cited by 33
Application of the FLP/FRT system for conditional gene deletion in yeast Saccharomyces cerevisiae
Park, Y., Masison, D. C., Eisenberg, E., & Greene, L. E. (2011) · Yeast · doi:10.1002/yea.1895 · Cited by 32
Expression of VHHs in Saccharomyces cerevisiae
Gorlani, A., de Haard, H., & Verrips, T. C. (2012) · Methods in molecular biology · doi:10.1007/978-1-61779-968-6_17 · Cited by 32
Model‐based analysis on the extractability of information from data in dynamic fed‐batch experiments
Wechselberger, P., Sagmeister, P., & Herwig, C. (2012) · Biotechnology Progress · doi:10.1002/btpr.1649 · Cited by 30
Self-citationJazini, M., & Herwig, C. (2011) · Journal of Bioscience and Bioengineering · doi:10.1016/j.jbiosc.2011.08.013 · Cited by 24
Self-citationCell Culture Processes in Monoclonal Antibody Production
Li, F., Shen, A. Y., & Amanullah, A. (2013) · Wiley eBooks · doi:10.1002/9780470571224.pse506 · Cited by 21
Utilization of Site-Specific Recombination for Generating Therapeutic Protein Producing Cell Lines
Campbell, M., Corisdeo, S., McGee, C., & Kraichely, D. (2010) · Molecular Biotechnology · doi:10.1007/s12033-010-9266-5 · Cited by 19
Leite, F. C. B., dos Anjos, R. S. G., Basílio, A. C. M., Leal, G. F. C., Simões, D. A., & de Morais, M. A. (2012) · Plasmid · doi:10.1016/j.plasmid.2012.09.004 · Cited by 14
Jalalirad, R. (2013) · Electronic Journal of Biotechnology · doi:10.2225/vol16-issue3-fulltext-15 · Cited by 13
COMPARISON OF THE CYTOPLASMIC AND PERIPLASMIC PRODUCTION OF RETEPLASE INEscherichia coli
Khodabakhsh, F., Zia, M. F., Moazen, F., Rabbani, M., & Hamid, M. (2013) · Preparative Biochemistry & Biotechnology · doi:10.1080/10826068.2013.764896 · Cited by 13
Cited by
Lee, H.-H., Wang, Y.-N., Xia, W., Chen, C.-H., Rau, K.-M., Ye, L., Wei, Y., Chou, C.-K., Wang, S.-C., Yan, M., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.06.008 · Cited by 405
Gmeiner, C., Saadati, A., Maresch, D., Krasteva, S., Frank, M., Altmann, F., Herwig, C., & Spadiut, O. (2015) · Microbial Cell Factories · doi:10.1186/s12934-014-0183-3 · Cited by 305
Self-citationDavid vs. Goliath: The Structure, Function, and Clinical Prospects of Antibody Fragments
Bates, A., & Power, C. A. (2019) · Antibodies · doi:10.3390/antib8020028 · Cited by 237
Brunner, M., Fricke, J., Kroll, P., & Herwig, C. (2017) · Bioprocess and Biosystems Engineering · doi:10.1007/s00449-016-1693-7 · Cited by 79
Self-citationPerfusion culture of Chinese Hamster Ovary cells for bioprocessing applications
MacDonald, M. A., Nöbel, M., Roche Recinos, D., Martínez, V. S., Schulz, B. L., Howard, C. B., Baker, K., Shave, E., Lee, Y. Y., Marcellin, E., et al. (2022) · Critical Reviews in Biotechnology · doi:10.1080/07388551.2021.1998821 · Cited by 55
Metadata
- Authors
- Spadiut, O., Capone, S., Krainer, F., Glieder, A., & Herwig, C.
- Venue
- Trends in Biotechnology
- Publisher
- Elsevier BV
- Published
- 2014-01
- Volume
- 32
- Issue
- 1
- Pages
- 54-60
- ISSN
- 0167-7799 (ISSN-L)
- OpenAlex
- W2050405684
- Cited by
- 258
- References
- 68
- FWCI
- 2.09
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.